---
title: "HBM Holdings Unveils Promising Preclinical Data for AI-Enabled Obesity Antibody LET003"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286689309.md"
description: "HBM Holdings Ltd. announced promising preclinical results for LET003, an AI-enabled monoclonal antibody targeting obesity. In animal models, LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, suggesting its potential as a leading obesity therapy. Analysts rate HBM stock as a Buy with a target price of HK$17.00, reflecting confidence in its innovative approach to obesity treatment."
datetime: "2026-05-18T00:07:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286689309.md)
  - [en](https://longbridge.com/en/news/286689309.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286689309.md)
---

# HBM Holdings Unveils Promising Preclinical Data for AI-Enabled Obesity Antibody LET003

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

HBM Holdings Ltd. ( (HK:2142) ) has shared an announcement.

HBM Holdings has reported promising preclinical results for LET003, its first AI-enabled, next-generation ACVR2A/2B-targeting monoclonal antibody for obesity treatment, developed on the Hu-mAtrIx platform. In animal models, LET003 showed superior pharmacokinetic properties to rival molecules, suggesting it could achieve similar efficacy at lower doses or with longer dosing intervals, which may enhance its competitiveness against existing therapies.

When combined with semaglutide in obesity models, LET003 significantly boosted fat reduction while mitigating lean mass loss, improving both absolute fat loss and lean mass preservation versus semaglutide alone. Additional studies in high-fat diet and normal diet models showed that LET003 improved body composition and promoted lean mass more effectively than comparator antibodies, underscoring its potential as a best-in-class obesity therapy and strengthening HBM’s positioning in the rapidly evolving obesity treatment landscape.

The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

**More about HBM Holdings Ltd.**

HBM Holdings Limited is a biotechnology company focused on developing innovative antibody-based therapies using its Hu-mAtrIx platform. The group targets major chronic conditions, with a growing emphasis on obesity and metabolic diseases, positioning itself in the competitive global biopharmaceutical and obesity-treatment markets.

**Average Trading Volume:** 3,429,966

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$11.38B

### Related Stocks

- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [02142.HK](https://longbridge.com/en/quote/02142.HK.md)

## Related News & Research

- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)